Page last updated: 2024-08-23

oltipraz and Angiosarcoma

oltipraz has been researched along with Angiosarcoma in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Angeles, T; Clapper, ML; Robinson, C; Ruggeri, BA; Wilkinson, J1

Other Studies

1 other study(ies) available for oltipraz and Angiosarcoma

ArticleYear
The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Cell Division; Dose-Response Relationship, Drug; Endothelium, Vascular; Hemangiosarcoma; Humans; Insulin-Like Growth Factor I; Liver; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Pyrazines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 4; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Ribonuclease, Pancreatic; Thiones; Thiophenes; Transplantation, Heterologous; Tumor Cells, Cultured

2002